This randomized, open-label, multicenter phase III trial is evaluating the efficacy and safety and tolerability of perioperative chemotherapy in combination with intraoperative `Hyperthermic IntraPEritoneal Chemotherapy' (HIPEC) for resectable adenocarcinoma of the stomach or gastroesophageal junction
